SEC INSIDER TRANSACTIONS

GILEAD SCIENCES, INC. (GILD) Insider Transactions

Explore official ownership filings, with every record linked to its source.

Reported data · not live

GILD · GILEAD SCIENCES, INC.

Filing window SEC codes (comma separated) Security type Order

More transaction filters

Roles: director,officer,ten_percent_owner,otherOwner nameOfficer titleOwnership: D, I, unknownoriginal or amendedTransaction fromTransaction throughFiled fromFiled throughMinimum quantityMaximum quantityMinimum priceMaximum priceMinimum calculated valueMaximum calculated valueResults per page (1–100)

OR within codes/roles; AND between categories. Roles apply to buyers and sellers. Owner predicates match the same owner. Missing values fail numeric/date filters. Value is quantity × reported price for non-derivative rows only; derivative values are unknown. Amendments stay separate; joint owners do not duplicate rows.

Reset filters

Active filters: days=6m

Stale snapshot · Covered: filings 2026-05-14 to 2026-11-13 · 34 filings · fetched 2026-11-13T18:00:06Z

Recent reported activity

0purchase rows on this page

10sale rows on this page

110matching filing rows

Purchases and sales count original non-derivative P and S rows. Awards, gifts, exercises, derivatives and amendments are shown separately and are not described as market purchases.

Transaction / filed	Reporting owner(s)	Code / security	Quantity	Price as filed	Ownership	Source
2026-08-03Filed 2026-08-04	O'Day Daniel PatrickDirector · Officer · Chairman & CEO Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 25, 2026. F2 Sale prices for the transactions reported range from $129.17 to $130.16. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request. F3 Sale prices for the transactions reported range from $130.18 to $131.17. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request. F4 Sale prices for the transactions reported range from $131.21 to $131.47. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request. References: F1, F3	S Sale (market/private)Common Stock · Non-derivative	7,700D	130.8022	Direct	Form 4 ↗0001638643-26-000028
2026-08-03Filed 2026-08-04	O'Day Daniel PatrickDirector · Officer · Chairman & CEO Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 25, 2026. F2 Sale prices for the transactions reported range from $129.17 to $130.16. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request. F3 Sale prices for the transactions reported range from $130.18 to $131.17. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request. F4 Sale prices for the transactions reported range from $131.21 to $131.47. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request. References: F1, F2	S Sale (market/private)Common Stock · Non-derivative	6,700D	129.6583	Direct	Form 4 ↗0001638643-26-000028
2026-07-15Filed 2026-07-16	Mercier JohannaOfficer · Chief Comm & Corp Aff Officer Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 20, 2025. F2 Sale prices for the transactions reported range from $129.45 to $130.23. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request. References: F1, F2	S Sale (market/private)Common Stock · Non-derivative	3,000D	129.9192	Direct	Form 4 ↗0001782135-26-000026
2026-07-15Filed 2026-07-16	Dickinson Andrew DOfficer · Chief Financial Officer Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on August 29, 2024. F2 Sale prices for the transactions reported range from $129.45 to $130.08. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request. References: F1, F2	S Sale (market/private)Common Stock · Non-derivative	3,000D	129.9256	Direct	Form 4 ↗0001310204-26-000022
2026-07-01Filed 2026-07-02	O'Day Daniel PatrickDirector · Officer · Chairman & CEO Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 25, 2026. F2 Sale prices for the transactions reported range from $125.59 to $126.55. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request. F3 Sale prices for the transactions reported range from $126.595 to $127.44. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request. References: F1, F3	S Sale (market/private)Common Stock · Non-derivative	3,100D	127.075	Direct	Form 4 ↗0001638643-26-000026
2026-07-01Filed 2026-07-02	O'Day Daniel PatrickDirector · Officer · Chairman & CEO Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 25, 2026. F2 Sale prices for the transactions reported range from $125.59 to $126.55. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request. F3 Sale prices for the transactions reported range from $126.595 to $127.44. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request. References: F1, F2	S Sale (market/private)Common Stock · Non-derivative	11,900D	126.0897	Direct	Form 4 ↗0001638643-26-000026
2026-06-15Filed 2026-06-16	Mercier JohannaOfficer · Chief Comm & Corp Aff Officer Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 20, 2025. F2 Sale prices for the transactions reported range from $122.79 to $123.785. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request. F3 Sale prices for the transactions reported range from $123.81 to $124.23. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request. References: F1	S Sale (market/private)Common Stock · Non-derivative	450D	125.4	Direct	Form 4 ↗0001782135-26-000024
2026-06-15Filed 2026-06-16	Mercier JohannaOfficer · Chief Comm & Corp Aff Officer Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 20, 2025. F2 Sale prices for the transactions reported range from $122.79 to $123.785. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request. F3 Sale prices for the transactions reported range from $123.81 to $124.23. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request. References: F1, F3	S Sale (market/private)Common Stock · Non-derivative	1,070D	123.9958	Direct	Form 4 ↗0001782135-26-000024
2026-06-15Filed 2026-06-16	Mercier JohannaOfficer · Chief Comm & Corp Aff Officer Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 20, 2025. F2 Sale prices for the transactions reported range from $122.79 to $123.785. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request. F3 Sale prices for the transactions reported range from $123.81 to $124.23. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request. References: F1, F2	S Sale (market/private)Common Stock · Non-derivative	1,480D	123.4166	Direct	Form 4 ↗0001782135-26-000024
2026-06-15Filed 2026-06-16	Dickinson Andrew DOfficer · Chief Financial Officer Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on August 29, 2024. References: F1	S Sale (market/private)Common Stock · Non-derivative	3,000D	125.4	Direct	Form 4 ↗0001310204-26-000020
2026-06-10Filed 2026-06-11	Cain Wettan Keeley MOfficer · EVP Gen Counsel, Legal & Comp Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. References: F1, F2	M Exercise / conversionRestricted Stock Unit · Derivative	589D	—	Direct	Form 4 ↗0002110603-26-000008
2026-06-10Filed 2026-06-11	Cain Wettan Keeley MOfficer · EVP Gen Counsel, Legal & Comp Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. References:	F WithholdingCommon Stock · Non-derivative	283D	121.48	Direct	Form 4 ↗0002110603-26-000008
2026-06-10Filed 2026-06-11	Cain Wettan Keeley MOfficer · EVP Gen Counsel, Legal & Comp Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. References: F1	M Exercise / conversionCommon Stock · Non-derivative	589A	—	Direct	Form 4 ↗0002110603-26-000008
2026-06-10Filed 2026-06-11	Mercier JohannaOfficer · Chief Comm & Corp Aff Officer Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 The restricted stock units have a 4-year vesting schedule. 25% vest on the first anniversary of the grant date. The balance will vest 6.25% quarterly thereafter until fully vested. References: F1, F2	M Exercise / conversionRestricted Stock Unit · Derivative	2,796D	—	Direct	Form 4 ↗0001782135-26-000022
2026-06-10Filed 2026-06-11	Mercier JohannaOfficer · Chief Comm & Corp Aff Officer Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 The restricted stock units have a 4-year vesting schedule. 25% vest on the first anniversary of the grant date. The balance will vest 6.25% quarterly thereafter until fully vested. References:	F WithholdingCommon Stock · Non-derivative	1,341D	121.48	Direct	Form 4 ↗0001782135-26-000022
2026-06-10Filed 2026-06-11	Mercier JohannaOfficer · Chief Comm & Corp Aff Officer Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 The restricted stock units have a 4-year vesting schedule. 25% vest on the first anniversary of the grant date. The balance will vest 6.25% quarterly thereafter until fully vested. References: F1	M Exercise / conversionCommon Stock · Non-derivative	2,796A	—	Direct	Form 4 ↗0001782135-26-000022
2026-06-10Filed 2026-06-11	Berger DietmarOfficer · Chief Medical Officer Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 The restricted stock units have a 4-year vesting schedule. 25% vest on the first anniversary of the grant date. The balance will vest 6.25% quarterly thereafter until fully vested. References: F1, F2	M Exercise / conversionRestricted Stock Unit · Derivative	533D	—	Direct	Form 4 ↗0001739515-26-000008
2026-06-10Filed 2026-06-11	Berger DietmarOfficer · Chief Medical Officer Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 The restricted stock units have a 4-year vesting schedule. 25% vest on the first anniversary of the grant date. The balance will vest 6.25% quarterly thereafter until fully vested. References:	F WithholdingCommon Stock · Non-derivative	263D	121.48	Direct	Form 4 ↗0001739515-26-000008
2026-06-10Filed 2026-06-11	Berger DietmarOfficer · Chief Medical Officer Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 The restricted stock units have a 4-year vesting schedule. 25% vest on the first anniversary of the grant date. The balance will vest 6.25% quarterly thereafter until fully vested. References: F1	M Exercise / conversionCommon Stock · Non-derivative	533A	—	Direct	Form 4 ↗0001739515-26-000008
2026-06-10Filed 2026-06-11	O'Day Daniel PatrickDirector · Officer · Chairman & CEO Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. References: F1, F2	M Exercise / conversionRestricted Stock Unit · Derivative	8,779D	—	Direct	Form 4 ↗0001638643-26-000024
2026-06-10Filed 2026-06-11	O'Day Daniel PatrickDirector · Officer · Chairman & CEO Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. References:	F WithholdingCommon Stock · Non-derivative	4,213D	121.48	Direct	Form 4 ↗0001638643-26-000024
2026-06-10Filed 2026-06-11	O'Day Daniel PatrickDirector · Officer · Chairman & CEO Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. References: F1	M Exercise / conversionCommon Stock · Non-derivative	8,779A	—	Direct	Form 4 ↗0001638643-26-000024
2026-06-10Filed 2026-06-11	Dickinson Andrew DOfficer · Chief Financial Officer Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 The restricted stock units have a 4-year vesting schedule. 25% vest on the first anniversary of the grant date. The balance will vest 6.25% quarterly thereafter until fully vested. References: F1, F2	M Exercise / conversionRestricted Stock Unit · Derivative	2,796D	—	Direct	Form 4 ↗0001310204-26-000018
2026-06-10Filed 2026-06-11	Dickinson Andrew DOfficer · Chief Financial Officer Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 The restricted stock units have a 4-year vesting schedule. 25% vest on the first anniversary of the grant date. The balance will vest 6.25% quarterly thereafter until fully vested. References:	F WithholdingCommon Stock · Non-derivative	1,341D	121.48	Direct	Form 4 ↗0001310204-26-000018
2026-06-10Filed 2026-06-11	Dickinson Andrew DOfficer · Chief Financial Officer Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 The restricted stock units have a 4-year vesting schedule. 25% vest on the first anniversary of the grant date. The balance will vest 6.25% quarterly thereafter until fully vested. References: F1	M Exercise / conversionCommon Stock · Non-derivative	2,796A	—	Direct	Form 4 ↗0001310204-26-000018

Imported instruments only. Joint owners do not multiply transactions. Amendments are separate filing rows, not additional trades. No aggregate trade totals are implied.